Key Highlights
- AngioDynamics filed two amendments on September 29, 2026 to its Annual Report for the fiscal year ended May 31, 2026.
- Amendment No. 1 adds the Part III information on directors, executive compensation, ownership and related matters.
- Amendment No. 2 was filed solely to add inline XBRL tagging to the Part III information, with no substantive changes.
- The Part III content covers an eight-member board in three classes and five named executive officers, including CEO James Clemmer.
AngioDynamics Inc (NASDAQ:ANGO) filed two amendments to its Annual Report on Form 10-K for the fiscal year ended May 31, 2026 on September 29, 2026. Amendment No. 1, accession 0001140361-26-037943, adds the Part III information.
Amendment No. 2, accession 0001140361-26-037995, was filed, in the company's words, "solely to include inline XBRL tagging to certain information required by Part III of Form 10-K which was inadvertently incomplete at the time of the Company's previous filing." Amendment No. 2 makes no substantive changes.
Amendment No. 1: Adding Part III
The explanatory note to Amendment No. 1 says it was filed solely to include the information required by Part III of Form 10-K. Part III covers directors, executive officers and corporate governance, executive compensation, security ownership, related transactions and director independence, and principal Accountant fees. Companies may leave these items out of the annual report and instead incorporate them by reference from a proxy statement filed within 120 days after the fiscal year end. The note does not say why the information was provided directly in the amendment rather than by reference to a proxy statement.
The amendment states that no other items of the original Form 10-K have been amended or revised. It lists Items 10 through 14 and describes a board of eight directors organized into three staggered classes. The directors named are Eileen O. Auen, Lorinda A. Burgess, Howard W. Donnelly, Wesley E. Johnson Jr., Karen A. Licitra, Jan Stern Reed, Michael E. Tarnoff and James C. Clemmer.
Amendment No. 2: the XBRL Correction
Amendment No. 2 has a narrower purpose. Inline XBRL is the format that embeds machine-readable tags in the text of a filing so that specific data points can be read by software. The explanatory note says the Part III information filed in the earlier amendment was inadvertently incomplete in that tagging, and that the new amendment was filed solely to add the tags.
The amendment reproduces the Part III content, covering an eight-member board with committee assignments, executive compensation for five named executive officers including Chief Executive Officer James Clemmer, security ownership and Equity plan information, related transactions and independence, and accounting fees. Named executives include Stephen Trowbridge, the Chief Financial Officer, and Lawrence Weiss, Senior Vice President and Chief Legal Officer, along with Laura Piccinini and Warren Nighan. The filing also carries the required exhibits, including certifications from the company's principal officers.
Both amendments cover the fiscal year ended May 31, 2026, and both include XBRL data files, which is the machine-readable layer that the second amendment was filed to complete. Each was filed on the same day, September 29, 2026, and each is a complete Part III document rather than a short cover note.
The Business Behind the Filing
AngioDynamics is a Delaware corporation based in Latham, New York, and the EDGAR index describes it as a medical instruments manufacturer. Its fiscal year ends on May 31. The amendments are administrative in nature. They do not include new financial results, guidance or transactions, and they do not restate any previously reported numbers.
AngioDynamics' Amendments and the Original Annual Report
The filing sets no vote, deadline or approval date. Any further correction would have to be filed as another amendment, and these filings do not indicate that one is planned. The original 10-K, filed earlier, remains the source for the company's business description and financial statements.






Please wait processing your request...